Oxigene Gets Development Funds For Zybrestat In Collaboration With Symphony
This article was originally published in The Pink Sheet Daily
Executive Summary
Unique deal structure creates new company to develop Zybrestat for ophthalmology and second oncologic while giving Oxigene option for reacquisition.